Novo Nordisk's Failed Heart Drug Trial Wipes Out $20.5 Billion in Market Value

Novo Nordisk's experimental anti-inflammatory drug Ziltivekimab missed its primary endpoint in a Phase 3 trial, wiping out $20.5B in market value and raising doubts about its diversification strategy.

The Danish pharmaceutical giant's ambitious push beyond its weight-loss and diabetes empire has hit a wall. Novo Nordisk's experimental anti-inflammatory drug Ziltivekimab failed its pivotal Phase 3 trial on Friday, triggering one of the steepest single-day declines in the company's recent history and erasing roughly $20.5 billion in market capitalization.

A Null Result That Stings

The ZEUS study, which enrolled more than 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and elevated inflammatory markers, tested whether a monthly antibody targeting interleukin-6 could reduce major adverse cardiac events. While the drug did lower the inflammatory biomarkers IL-6 and hsCRP as expected, the primary composite endpoint — cardiovascular death, non-fatal heart attack, and stroke — showed no meaningful improvement. The hazard ratio came in at 0.99 with a confidence interval of 0.88 to 1.11, statistically indistinguishable from placebo.

Compounding the disappointment, patients receiving Ziltivekimab experienced a higher rate of serious infections, while overall mortality showed no difference between the treatment and placebo groups. Novo Nordisk has flagged a non-cash impairment charge for the third quarter of 2026 but reiterated that its full-year operating profit guidance — which already projects a 4 to 12 percent decline in adjusted operating income — remains unchanged.

The Market's Verdict

Investors wasted no time heading for the exits. In Frankfurt, shares closed Friday at EUR 40.90, down 8.48 percent on the day. The stock now sits 25.45 percent below its 52-week high of EUR 54.86, reached as recently as January. Across the Atlantic, the ADR fell 9.18 percent to $46.85, while Copenhagen saw losses of roughly 7 percent.

The damage extended beyond Novo Nordisk itself. Shares of other biotech companies pursuing similar inflammation-based approaches came under pressure as investors questioned whether hsCRP reduction is a reliable predictor of clinical benefit. Monte Rosa Therapeutics took the hardest hit, plunging 27.5 percent, with BioAge Labs, Neurocrine Biosciences, and Neumora Therapeutics also sliding.

Analysts at Jefferies and Citi both characterized the market's reaction as overdone, yet they acknowledged the setback carries strategic weight. Ziltivekimab — acquired through the $725 million takeover of Corvidia in 2020 — was meant to be a cornerstone of Novo Nordisk's diversification beyond its blockbuster diabetes and obesity franchise. That dependency is now painfully exposed: GLP-1 products accounted for roughly 94 percent of adjusted revenues in the first quarter of 2026.

A Worsening Backdrop

The trial failure lands at an awkward moment for the company. Prescription data from Barclays, based on Iqvia figures, shows weekly scripts for the Wegovy pill in the US holding steady at around 110,600 — a slight dip from 110,900 the prior week. Citi's alternative counting method puts the figure at 171,788, but similarly indicates a plateau. Meanwhile, Eli Lilly's competing oral treatment posted a 16 percent week-over-week gain over the same period.

Citi analyst Graham Parry noted that after the previous week's uptick, the Wegovy oral business is now flat — hardly the momentum Novo Nordisk needs as it fends off intensifying competition in the GLP-1 arena.

What Comes Next

The technical picture offers some nuance. Despite Friday's rout, the stock remains about 1.35 percent above its 200-day moving average, suggesting the longer-term trend hasn't fully broken down. The relative strength index sits at 41.8, pointing to neither oversold conditions nor imminent recovery.

With a price-to-earnings ratio near 11 — close to multi-year lows — some market observers see a potential buying opportunity, particularly given the still-expanding global GLP-1 market. Others prefer to wait for clarity.

All eyes now turn to August 5, when Novo Nordisk releases its first-half results. The earnings call will likely provide the first formal assessment of how management views the ZEUS outcome and whether the company's 2026 guidance holds. Beyond that, two related studies — HERMES and ARTEMIS — are still running, with results expected in the first half of 2027. They will determine whether Ziltivekimab can demonstrate value in different patient populations, or whether Novo Nordisk's anti-inflammatory strategy remains an open question mark.

Research chief Martin Holst Lange struck a measured tone, saying the findings will inform ongoing development efforts and that the company's strategic direction is unchanged. For shareholders, though, the immediate calculus is simpler: a key pillar of the diversification story has crumbled, and the core business now carries even more weight than before.